

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. categorical variables, and adjusted logistic regression was used to compare MSOF rates.

Results: We identified a total of 48,066 patients treated at the VA who had contracted COVID-19 during the study period. Of these patients, 879 (1.8%) were receiving chronic therapeutic anticoagulation before contracting COVID-19. The anticoagulation regimens included apixaban (55.6%), rivaroxaban (19.1%), and warfarin (15.5%). Patients receiving anticoagulation were more likely to be older (72 vs 59; P < .01) and to have cardiovascular risk factors such as diabetes (56.8% vs 31.4%; P < .01), hypertension (91.8% vs 54.5%; P < .01), hyperlipidemia (84.6% vs 53.6%; P < .01), and coronary disease (46.9% vs 15.3%; P < .01). They were also more likely to have a history of venous thromboembolism (25.3% vs 3.3%; P <.01). Despite the greater comorbidity rates for patients receiving anticoagulation, no differences were observed in ICU admission (24.9% vs 23.6%; P = .7) and hospital/ICU mortality rates (11.2% vs 10.2%; P = .5). Logistic regression analysis adjusted for cardiovascular morbidity indicated that among patients with prior venous thromboembolism, those who had received outpatient anticoagulation had a 55% decreased odds of composite MSOF (odds ratio, 0.45: P = .002).

**Conclusions:** Our large retrospective database analysis is the first to suggest that outpatient therapeutic anticoagulation might have a beneficial effect on patients with cardiovascular risk factors after COVID-19 infection. Unlike previous studies, which demonstrated that patients with advanced age, diabetes, and cardiovascular disease have increased in-hospital mortality, our study observed that these higher risk individuals had notably lower rates of hospital/ICU admission, MSOF, and ICU mortality.

	Outpatient anticoagulation					
		All		Hospitalized		
Cohort	No	Yes	P value	No	Yes	P value
Patients, No.	47,187	879		9352	29	
Demographics						
Age, years	59	72	<.05	69	73	<.05
Diabetes, %	31.4	56.8	<.05	77.0	94.2	<.05
Hypertension, %	54.5	91.8	<.05	94.2	77.0	<.05
Hyperlipidemia, %	53.6	84.6	<.05	69.6	83.0	<.05
Coronary artery disease, %	15.3	46.9	<.05	27.7	51.7	<.05
Venous thromboembolism, %	3.3	25.3	<.05	7.2	28.9	<.05
Outcomes, %						
Intensive care unit admission	4.7	9.3	<.05	23.6	24.9	.74
Intensive care unit death	2.0	4.2	<.05	10.2	11.2	.54
Hospital death	1.7	4.0	<.05	8.8	10.6	.24

Author Disclosures: K. Chadwick-Mansker: Nothing to disclose; A. K. Gibson: Nothing to disclose; Y. Yan: Nothing to disclose; M. A. Zayed: Nothing to disclose.

### **RS09**.

# Clinical Outcomes in Peripheral Artery Disease With Coronavirus Disease 2019: A Multicenter Research Network Study

Danielle Kim,<sup>1</sup> Ahsan Zil E. Ali,<sup>2</sup> Faisal Aziz,<sup>2</sup> Lawrence Sinoway<sup>2</sup>. <sup>1</sup>Penn State Hershey College of Medicine, Hershey, Pa; <sup>2</sup>Penn State Hershey Medical Center, Hershey, Pa **Objective**: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19) infection has resulted in a global pandemic, and it has been shown that patients with comorbidities have worse clinical outcomes from COVID-19 compared with otherwise healthy patients. Peripheral artery disease (PAD) is an atherosclerotic occlusive disease in the periphery affecting 8 to 12 million U.S. adults. However, whether PAD patients have worse clinical outcomes with SARS-CoV-2 infection remains unknown. Accordingly, the primary aim of our study was to examine the clinical outcomes of COVID-19 patients with PAD and determine whether they have an increased risk of mortality, hospitalization, and ventilator dependence.

**Methods:** A real-time search and analysis were performed for patients diagnosed with COVID-19 using the TriNetX (Cambridge, Mass) research network, a global federated health research network providing access to electronic medical records (diagnoses, procedures, medications, laboratory values) from ~63 million patients in 45 large healthcare organizations. The TriNetX platform only uses aggregated counts and statistical summaries of de-identified information. We identified COVID-19 patients (age,  $\geq 60$  years) with preexisting PAD (n = 964) and without PAD (n = 52,667). The two groups were compared for the risk of 28-day mortality, hospitalization, and ventilator dependence with and without propensity score matching for confounding factors.

**Results:** We used propensity score matching to match the COVID-19 patients with and without PAD for age, sex, race, and comorbidities. Before propensity score matching, COVID-19 patients with PAD had significantly higher mortality (risk ratio [RR], 2.09; 95% confidence interval [CI], 1.78-2.46; *P* < .0001), hospitalization (RR, 1.54; 95% CI, 1.46-1.63; *P* < .0001), and ventilator dependence (RR, 2.06; 95% CI, 1.61-2.64; *P* < .0001) compared with the COVID-19 patients without PAD. After propensity score matching, the COVID-19 patients with PAD still had a greater risk of 28-day hospitalization (RR, 1.24; 95% CI, 1.14-1.34; *P* < .0001) compared with the COVID-19 patients with PAD still had a greater risk of 28-day hospitalization (RR, 1.24; 95% CI, 1.14-1.34; *P* < .0001) compared with the COVID-19 patients without PAD.

**Conclusions:** In general, COVID-19 patients with PAD have a lower survival probability, a higher rate of hospital admission, and a higher likelihood of requiring a ventilator compared with COVID-19 patients without PAD. Moreover, even after adjusting for comorbidities and confounding factors, compared with the non–PAD COVID-19 patients, the COVID-19 patients with PAD had a greater chance of requiring hospital admission. This finding suggests that PAD is an important risk factor for short-term hospital admission for patients with COVID-19.

Author Disclosures: F. Aziz: Nothing to disclose; D. Kim: Nothing to disclose; L. Sinoway: Nothing to disclose; A. Zil E Ali: Nothing to disclose.

SS09.

# The Coronavirus Disease 2019 Likelihood of Thrombosis Calculator: Predicting Venous Thromboembolism Risk in Hospitalized Patients With Coronavirus Disease 2019

Richard A. Meena, Mengyu Di, Rachel E. Patzer, Manila Gaddh, Fadi B. Nahab, Olamide Alabi. Emory University, Atlanta, Ga

**Objective:** Emerging data have suggested that venous thromboembolism (VTE) occurrence in those with coronavirus disease 2019 (COVID-19) is associated with higher mortality rates. However, a paucity of data is available exploring which patients with COVID-19 have the highest risk of VTE development. Furthermore, no clear consensus has been reached regarding which patients warrant more or less aggressive antithrombotic therapy. We sought to develop a risk model to help clinicians predict which patients with COVID-19 might be more prone to VTE development.

**Methods:** A prospectively maintained registry of all COVID-19–related admissions between March and September 2020 was reviewed. Administrative database coding and medical record review were used to individually confirm the VTE diagnosis. Routine venous duplex ultrasound surveillance was not performed. Univariate and multivariate analyses **Results:** A total of 2552 patients were admitted with COVID-19– related illnesses, 126 (4.9%) of whom had developed an in-hospital VTE. The in-hospital mortality rate was 9.4%, and the 90-day mortality rate was 11.0%. VTE was independently associated with mortality (odds ratio, 3.59; 95% confidence interval, 2.33-5.54). Univariate and multivariate analyses demonstrated that multiple patient-level, hospital course, and laboratory biomarkers were associated with VTE development (Table). Age >65 years, birth sex, race, markers of coagulation and hemostatic activation profile score, negative D-dimer result, maximum D-dimer level, history of hypertension, intensive care unit status, insurance status, and median family income extrapolated by zip code were included to build the predictive model. The developed risk calculator demonstrated a positive predictive value of 97.7%, sensitivity of 70.2%, and specificity of 73.2%, with an area under the receiver operating characteristic curve of 0.77 and concordance statistic of 0.73 (Fig).

**Conclusions:** VTE development is independently associated with mortality in patients hospitalized with COVID-19. Prevention and/or early treatment of VTE among patients with COVID-19 could save lives. Our CLOT (COVID-19 likelihood of thrombosis) prediction model can assist with risk stratification for VTE development among COVID-19 admissions and better inform clinical decision-making regarding institutional antithrombotic protocols to reduce the bleeding risk and improve outcomes. Further studies are required to validate this model among other national clinical registries.

Table. Odds ratios for some factors in univariate and multivariate analyses, including factors constituting the CLOT prediction model

Ris factor         Yes (n 126)         Yes (n 226)         Yes (n 956)         Paule         ApR "95% (n )         Yes (n 126)           Age. years         -		VTE dev	relopment	Univariate analysis		Multivariate analysis		
Age, searsSequenceSet of Sec on Sec o	Risk factor	Yes (n = 126)	No (n = 2426)	Crude OR (95% CI)	<i>P</i> value	aOR <sup>a</sup> (95% CI)	<i>P</i> value	
>S5?2 (S7.4)1516 (62.4)125 (0.85.17)2855 yes (0.91071)131 (0.82.08)?2?2i G554 (42.6)90 (07.5)NANANANANABirths121 (49.0)103 (0.72.14)76.0137 (0.39.213)147Made62 (42.0)121 (49.0)NANANANANARace121 (49.0)NANANANANARace90 (75.0)140 (63.02.58)0.50 <td>Age, years</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Age, years							
≤6554 (42.69)910 (37.51)NANANANANABirth sexFernale62 (49.21)1215 (50.08)103 (0.72-147)876137 (0.89-213)1A7Male62 (49.21)1211 (49.22)NANANANANARace90 (77.59)163 (0.10 3-258)6380.60163505Other2 (17.02)90 (75.23)163 (1.03 2-258)4310.70 (015-23)505White24 (20.69)607 (28.32)NANANANAEthicit119.41247 (114.71)0.80 (0.42-151)433NANANon-Hispanic/Latinx106 (90.6)1906 (88.53)NANANANANANon-Hispanic/Latinx106 (90.6)1906 (88.52)NANANANAILU status1555 (68.22)NANANANANAINCHA profile score122 (96.31)2550 (62.16)AG4NANANAOC 44 (517)157 (53.9)0.56 (0.23-21)864113 (0.44-24)784210 (79.4)196 (68.0)10.60 (52.216)86413.60 (40.42-4)784312 (95.2)166 (68.4)15.50 (62.243)81413.60 (40.42-4)784418 (14.2)185 (63.2)16.60 (53.216)86413.60 (40.42-4)784512 (95.2)166 (68.4)15.50 (62.243)81413.60 (40.42-4)784613 (14.92)185	>65	72 (57.14)	1516 (62.49)	1.23 (0.85-1.77)	.26S65 years, univariate analysis.	1.31 (0.83-2.08)	.247	
Bith setIf the setNale64 (60)121 (50.00)NANA137 (3.0.9.2.13)MARecBlack90 (7.05)163 (0.52.52).0380.63 (0.4.3.14).505Other2 (1.20)91 (4.0.0).056 (0.15.2.50).038.0.71 (0.1.3.2.3).516White2 (1.20).0.61 (0.1.5.2.50).0.33.0.71 (0.1.3.2.3).516White2 (1.20).0.61 (0.1.5.2.50).0.34.0.71 (0.1.3.2.3).516White.0.61 (0.1.5.2.5).0.74.0.74.716.716Non-Hispanic/Latinx.0.61 (0.1.5.2.5).0.74.0.74.716.716Non-Hispanic/Latinx.0.61 (0.1.5.2.5).0.74.0.74.716.716Non-Hispanic/Latinx.0.61 (0.1.7.5.5).0.74.716 <td>≤65</td> <td>54 (42.86)</td> <td>910 (37.51)</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td>	≤65	54 (42.86)	910 (37.51)	NA	NA	NA	NA	
Fenale64 (50.79)1.215 (50.08)1.03 (0.72-147)8.761.37 (0.89-213)1.47Male62 (49.20)21 (1.99.2)NANANANARaceBlack90 (77.59)1.400 (66.73)1.65 (1.05-258).0380.83 (0.48-146).505Other2 (1.72)91 (4.34)0.56 (0.15-239).4310.70 (1.05-23).586White2 (20.08)607 (28.30)0.56 (0.15-239).4330.70 (1.05-23).586Uthicity55.500.500.500.500.500.500.500.500Clustatis11 (9.4)2.47 (1.47)0.80 (0.42-15).493.500.5	Birth sex							
Male62 (92)121 (92)NANANANANANARaceBlack90 (750)151 (0.026)6316330.03 (0.40-16)560Other21 (72)91 (43)056 (0.12-23)A34OX10 (0.12-23)580White24 (260)607 (283)NANANANAEthing10 (10 (20 (20 (20 (20 (20 (20 (20 (20 (20 (2	Female	64 (50.79)	1215 (50.08)	1.03 (0.72-1.47)	.876	1.37 (0.89-2.13)	.147	
Race         Start         Start <ths< td=""><td>Male</td><td>62 (49.21)</td><td>1211 (49.92)</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></ths<>	Male	62 (49.21)	1211 (49.92)	NA	NA	NA	NA	
Black90 (7759)1400 (6673)163 (103-258) <b>0.08</b> 0.083 (0.48-1.46).505Other2 (1.2)91 (4.34)0.56 (0.13-2.3)A.310.7 (0.13-2.3).586White2 4 (20.69)0.20 (20.83)NANANANAEthnicity11 (9.4)2.47 (11.47)0.80 (0.42-1.51).493NANANon-Hispanic/Latinx106 (9.0)1906 (88.3)NANANANARU2.47 (11.47)0.80 (0.42-1.51).493NANANARU106 (9.0)1906 (88.3)NANANANARU70 (55.5)7.71 (31.78)2.66 (1.87-3.85).60012 (0.74-195).471No56 (44.4)1655 (68.22)NANANANANAInsurance status71 (31.78)2.66 (1.87-3.85).600.718.718No12 (2.64.3)2.556 (0.27).763.78.781.781No42 (19.63)2.556 (0.20-1.51).645.781.78119 (71.4)155 (63.9).055 (0.20-1.51).645.716 (0.52-4.24)210 (7.94)126 (0.61.2-34).784.78119 (71.4)195 (63.63).781.716 (0.52-4.24).78419 (71.4)196 (80.63).616.716 (1.64 (	Race							
Other2 (1.72)9 (1.43)0.56 (0.13-2.39)4.310.7 (0.13-2.3)5.86White24 (20.69)0.7 (2.833)NANANANAEthnicityHispanic/Latinx11 (9.4)2.47 (11.47)0.80 (0.42-1.51)4.943NANANANon-Hispanic/Latinx106 (90.6)1906 (88.53)NANANANANAICU statusYes70 (55.6)7/1 (31.8)2.68 (1.87-3.85)<.001	Black	90 (77.59)	1400 (66.73)	1.63 (1.03-2.58)	.038	0.83 (0.48-1.46)	.505	
White24 (2069)607 (2893)NANANANANAEthicityHispin/Latinx11 (9.4)247 (11/7)0.00 (21.51).403NANANon-Hispanic/Latinx10 (9.00).906 (88.5)NANANANAIC ustrain.006 (88.5).NA.NANANANAIC strain.006 (88.5).NA.NA.NANANAIC strain.006 (88.5).NA.NA.NA.NA.NAIC strain.006 (88.5).NA.NA.NA.NA.NAIC strain.006 (88.5).NA<	Other	2 (1.72)	91 (4.34)	0.56 (0.13-2.39)	.431	0.7 (0.13-2.3)	.586	
Ethnicity         If Ispanic/Latinx         If It (A)         Q47 (IYA7)         Q80 (Q4215)         A93         NA         NA           Inon-Hispanic/Latinx         106 (Q)         Q40 (Q4215)         A93         NA         NA         NA           IU-Hispanic/Latinx         106 (Q403)         Q40 (Q4215)         A93         NA         NA         NA           IU-Hispanic/Latinx         70 (S55)         771 (G17)         Q60 (P-37.50)         A00         NA         NA           IV-Area         70 (S55)         771 (G17)         Q60 (P-37.50)         A00         NA         NA           IN-Area         56 (444)         Q55 (G52)         NA         NA         NA         NA           IN-Area         22 (G63)         75 (G13)         Of (O         A01         A01         A01           NOCHArofilescore          76 (G13)         Of (G13)         A24         A63 (OA1.40)         A74           1         9 (714)         179 (F38)         026 (O2.21)         G44         13 (O4.24.29)         G74           2         0 (G14)         179 (F38)         05 (O2.01.51)         Q42         Q40 (Q1.41.7)         G74           2         10 (F19.4)         156 (G39)         IA1	White	24 (20.69)	607 (28.93)	NA	NA	NA	NA	
Hispanic/Latinx         11 (9.4)         247 (11.47)         0.80 (0.42:15)         4.493         NA         NA           Non-Hispanic/Latinx         106 (90.6)         1906 (88.53)         NA         NA         NA         NA           ICU status         70 (55.50)         771 (37.8)         2.68 (-8.73.85)         <001	Ethnicity							
Non–Hispanic/Latinx         106 (90.6)         1906 (88.53)         NA         NA         NA         NA           ICU status         Yes         70 (55.56)         717 (17.8)         2.68 (1-87.3.85)         <.001	Hispanic/Latinx	11 (9.4)	247 (11.47)	0.80 (0.42-1.51)	.493	NA	NA	
LCJ status         Yes         70 (55.56)         77 (37.8)         2.68 (1-87.3.8)         <00         1.2 (0.74-1.95)         4.51           No         56 (44.4)         1655 (68.22)         NA         NA         NA         NA           Insurance status          12 (0.74-1.95)         4.51         NA         NA         NA         NA           Yes         12 (0.63)         255 (0.627)         0.9 (0.62-1.41)         7.6         2.55 (0.77-6.66)         7.17           No         4 (3.17)         275 (0.63)         NA         NA         NA         NA           MOCHarenee          4 (3.17)         155 (0.39)         0.55 (0.20-1.51)         2.65         1.63 (0.54.18)         3.78           1         9 (7.14)         179 (7.38)         1.06 (0.52.216)         8.64         1.13 (0.42.24)         .78           2         10 (7.94)         196 (8.04)         1.53 (0.81-2.80)         .864         1.32 (0.42.34)         .78           3         12 (9.52)         166 (6.84)         1.53 (0.81-2.80)         .86         .026 (0.61-2.43)         .74           4         4 (3 (7.9)         165 (6.32)         1.64         .74         .74         .74         .74         .74	Non–Hispanic/Latinx	106 (90.6)	1906 (88.53)	NA	NA	NA	NA	
Yes         70 (5556)         771 (31.78)         2.68 (1-87-3.85)         <.001         1.2 (0.74-1.95)         4.51           No         56 (44.44)         1655 (68.22)         NA         NA         NA         NA           Insurance status	ICU status							
No56 (444)1655 (6822)NANANANAInsurance statusYes122 (96.83)2350 (96.87)0.94 (0.62-14)).762.55 (0.77-6.86).17No4 (317)76 (313)NANANANAMOCHA profile score04 (317)155 (63.9)0.50 (20-15).461.13 (0.44-24.9).7810 (7.14)179 (7.38)1.06 (0.52-21).864.089 (0.41-16).7820 (7.94)196 (8.68)1.08 (0.55-21).824.089 (0.41-16).78312 (9.52)166 (6.84)1.53 (0.81-2.88).817.166 (0.24-31).314418 (4.29)1.55 (5.63.69).04.04.04.04NA73 (57.94)155 (5.63.69).04.04.04.04History of hypertensionYes95 (75.4)1724 (71.06)125 (0.82-189).296.066 (0.39-11.4).131No31 (24.6)702 (28.94).NA.NA.NA.NANegative D-dimer <sup>b</sup> Yes0 (0)357 (14.72).020 (0.10-37).008.004 (-0.29)No126 (0.00)206 (9.52.8).NA.NA.NA.NA.NAMaximum CRP, mg/L202 ± 130.12166 3.54 ±.001 (0.01.01)Hospital length of stat, d9156 ± 14.79 <td>Yes</td> <td>70 (55.56)</td> <td>771 (31.78)</td> <td>2.68 (1-87-3.85)</td> <td>&lt;.001</td> <td>1.2 (0.74-1.95)</td> <td>.451</td>	Yes	70 (55.56)	771 (31.78)	2.68 (1-87-3.85)	<.001	1.2 (0.74-1.95)	.451	
Insurance status         I22 (96.83         2350 (96.87)         0.94 (0.62-1.41)         7.6         2.55 (0.77-6.86)         1.17           No         4 (3.17)         76 (3.13)         NA         NA         NA         NA         NA           MOCHA profile score          4 (3.17)         155 (6.39)         0.55 (0.20-151)         2.45         1.63 (0.5-4.18)         .378           1         9 (7.14)         179 (7.38)         1.06 (0.52-2.16)         .864         1.13 (0.42-4.99)         .784           2         10 (7.94)         196 (8.08)         1.06 (0.52-2.16)         .864         .13 (0.42-4.9)         .784           3         12 (9.52)         166 (6.84)         .153 (0.81-2.88)         .824         0.89 (0.41-1.70)         .749           3         12 (9.52)         166 (6.84)         .153 (0.81-2.88)         .187         1.26 (0.61-2.43)         .514           4         18 (14.29)         185 (76.30)         2.06 (1.20-353)         .008         .071 (0.34-137)         .314           NA         NA         NA         NA         NA         NA         NA         NA           Negative D-chime <sup>16</sup> .25 (0.82-1.89)         .26 (0.63.9-1.14)         .313         .344         .3	No	56 (44.44)	1655 (68.22)	NA	NA	NA	NA	
Yes122 (96.83)2350 (96.87)0.94 (0.62-1.41).762.55 (0.77-6.86).17No4 (3.17)76 (3.13)NANANANAMOCHA profile score04 (3.17)155 (6.39)0.55 (0.20-1.51).2451.63 (0.54.18).37819 (7.14)179 (7.38)1.06 (0.52-2.16).8641.13 (0.44-2.49).764210 (7.94)196 (8.08)1.08 (0.55-2.13).8240.89 (0.41-176).749312 (9.52)1.66 (6.84)1.53 (0.81-2.88).187.126 (0.61-2.43).514418 (14.29)185 (7.63)2.06 (1.20-3.53).008.071 (0.34-1.37).314NA73 (57.94)1545 (63.69)NANANANAHistory of hypertension	Insurance status							
No4 (3.17)76 (3.13)NANANANANAMOCHA profile score04 (3.17)155 (6.39)0.55 (0.20-1.51)2451.63 (0.5-4.18)37819 (7.14)179 (7.38)1.06 (0.52-2.16).8641.13 (0.44-2.49).784210 (7.94)96 (8.08)1.08 (0.55-2.13).8240.89 (0.41.176).749312 (9.52)166 (6.84)1.53 (0.81-2.88).1871.26 (0.61-2.43).514418 (4.29).85 (7.63)2.06 (1.20-3.53).008.071 (0.34-1.37).314MA73 (57.94)1545 (63.69)NANANANAHistory of hypertension	Yes	122 (96.83)	2350 (96.87)	0.94 (0.62-1.41)	.76	2.55 (0.77-6.86)	.117	
MOCHA profile score           0         4 (3.7)         155 (6.39)         0.55 (0.20-1.51)         2.45         1.63 (0.5-4.16)         .378           1         9 (7.14)         179 (7.36)         1.06 (0.52-2.16)         .864         .1.3 (0.44-2.49)         .784           2         10 (7.94)         196 (8.08)         1.08 (0.55-2.13)         .824         0.89 (0.41-7.6)         .749           3         12 (9.52)         166 (6.84)         1.53 (0.81-2.88)         .187         1.26 (0.61-2.43)         .514           4         18 (14.29)         185 (7.63)         2.06 (1.20-3.53)         .008         .0.71 (0.34-1.37)         .314           NA         73 (57.94)         154 (56.66)         NA         NA         NA         NA           No         73 (57.94)         1724 (7.106)         1.25 (0.82-1.89)         .296         0.66 (0.39-1.14)         .311           No         31 (24.6)         702 (2.84)         NA         NA         NA         NA           Negative D-dimer <sup>b</sup> 126 (100)         250 (6.37.14)         .014         .014         .014         .014           No         126 (100)         206 (82.82)         NA         NA         NA         NA           No	No	4 (3.17)	76 (3.13)	NA	NA	NA	NA	
04 (317)155 (6.39)0.55 (0.20-1.51)2.451.63 (0.5-4.18).37819 (7.14)179 (7.38)1.06 (0.52-2.16).864.1.13 (0.44-2.49).784210 (7.94)196 (8.08)1.08 (0.55-2.13).8240.89 (0.41-1.76).749312 (9.52)166 (6.84).153 (0.81-2.88).187.126 (0.61-2.43).514418 (14.29)185 (7.63)2.06 (1 20-3.53).008.071 (0.34-1.37).314NA73 (57.94)1545 (63.69)NANANANAHistory of hypertension	MOCHA profile score							
19 (7.14)179 (7.38)1.06 (0.52-2.16).8641.13 (0.44-2.49).784210 (7.94)196 (8.08)1.08 (0.55-2.13).8240.89 (0.41-1.76).749312 (9.52)166 (6.64)1.53 (0.81-2.88).1871.26 (0.61-2.43).514418 (14.29)185 (7.63)2.06 (1 20-3.53).0080.71 (0.34-1.37).314NA73 (57.94)1545 (63.69)NANANANANAHistory of hypertension72.724 (71.06).125 (0.82-1.89).296.066 (0.39-1.14).131No31 (24.6)702 (28.94)NANANANANANegative D-dimer <sup>b</sup> 745.001.021 (0.01-037) <sup>c</sup> .0080.04 (0-0.29)<.001	0	4 (3.17)	155 (6.39)	0.55 (0.20-1.51)	.245	1.63 (0.5-4.18)	.378	
210 (7.94)196 (8.08)1.08 (0.55-2.13)8.240.89 (0.41-1.76)7.49312 (9.52)166 (6.84)1.53 (0.81-2.88)1.871.26 (0.61-2.43)5.14418 (14.29)185 (7.63)2.06 (1 20-3.53)0.080.71 (0.34-1.37)3.14NA73 (57.94)1545 (63 .69)NANANANAHistory of hypertension727.02 (28.94)NANANANANo31 (24.6)702 (28.94)NANANANANANegative D-dimer <sup>b</sup> 726 (00)357 (14.72)0.02 (0.01-0.37)c <b>.008</b> 0.04 (0-0.29) <b>.001</b> No126 (100)2069 (85.28)NANANANANAMaximum CRP, mg/L202.2 ± 130.12146.23 ± 111.811.00 (1 00-1.01) <b>.001</b> 1.00003 (1.00002-1.000) <b>001</b> Hospital length of stay, days135.6 ± 14.798.84 ± 9.591.03 (1 02-1.05) <b>.001</b> NANANA	1	9 (7.14)	179 (7.38)	1.06 (0.52-2.16)	.864	1.13 (0.44-2.49)	.784	
$3$ $12 (9.52)$ $166 (6.84)$ $1.53 (0.81-2.88)$ $1.87$ $1.26 (0.61-2.43)$ $5.14$ $4$ $18 (14.29)$ $185 (7.63)$ $2.06 (1 2.0.353)$ $0.08$ $0.71 (0.34-1.37)$ $3.14$ $NA$ $73 (57.94)$ $1545 (63.69)$ $NA$ $NA$ $NA$ $NA$ $NA$ History of hypertension $72 (71.06)$ $1.25 (0.82-1.89)$ $2.96$ $0.66 (0.39-1.14)$ $.131$ $No$ $31 (24.6)$ $702 (28.94)$ $NA$ $NA$ $NA$ $NA$ Negative D-dimer <sup>b</sup> $726 (0.01 - 0.37)^c$ $.008$ $0.04 (0-0.29)$ $<.001$ $No$ $126 (100)$ $357 (14.72)$ $0.02 (0.01-0.37)^c$ $.008$ $0.04 (0-0.29)$ $<.001$ $No$ $126 (100)$ $2069 (85.28)$ $NA$ $NA$ $NA$ $NA$ $NA$ Maximum CRP, mg/L $202.2 \pm 130.2$ $146.23 \pm 111.81$ $1.00 (1 00-1.01)$ $<.001$ $1.00003 (1.00002-1.00004) < .001$ Haspital length of stay, days $15.6 \pm 14.79$ $8.84 \pm 9.59$ $1.03 (1 02-1.05)$ $<.001$ $NA$ $NA$ $NA$	2	10 (7.94)	196 (8.08)	1.08 (0.55-2.13)	.824	0.89 (0.41-1.76)	.749	
418 (14.29)185 (7.63)2.06 (1 20-3.53).0080.71 (0.34-1.37).314NA73 (57.94)1545 (63.69)NANANANAHistory of hypertensionYes95 (75.4)1724 (71.06)1.25 (0.82-1.89).2960.66 (0.39-1.14).131No31 (24.6)702 (28.94)NANANANANegative D-dimer <sup>b</sup> Yes0 (0)357 (14.72)0.02 (0.01-0.37) <sup>c</sup> .0080.04 (0-0.29)<.001	3	12 (9.52)	166 (6.84)	1.53 (0.81-2.88)	.187	1.26 (0.61-2.43)	.514	
NA73 (57.94)1545 (63.69)NANANANANAHistory of hypertensionYes95 (75.4)1724 (71.06)1.25 (0.82-1.89)2.960.66 (0.39-1.14).131No31 (24.6)702 (28.94)NANANANANegative D-dimer <sup>b</sup> Yes0 (0)357 (14.72)0.02 (0.01-0.37) <sup>c</sup> .0080.04 (0-0.29)<.001	4	18 (14.29)	185 (7.63)	2.06 (1 20-3.53)	.008	0.71 (0.34-1.37)	.314	
History of hypertension       Yes       95 (75.4)       1724 (71.06)       1.25 (0.82-1.89)       .296       0.66 (0.39-1.14)       .131         No       31 (24.6)       702 (28.94)       NA       NA       NA       NA       NA         Negative D-dimer <sup>b</sup> 702 (28.94)       NA	NA	73 (57.94)	1545 (63 .69)	NA	NA	NA	NA	
Yes95 (75.4)1724 (71.06)1.25 (0.82-1.89).2960.66 (0.39-1.14).131No31 (24.6)702 (28.94)NANANANANegative D-dimer <sup>b</sup> Yes0 (0)357 (14.72)0.02 (0.01-0.37) <sup>c</sup> <b>.008</b> 0 04 (0-0.29) <b>&lt;.001</b> No126 (100)2069 (85.28)NANANANAMaximum CRP, mg/L202.2 ± 130.1214623 ± 111.811.00 (1 00-1.01) <b>&lt;.001</b> NANAMaximum D-dimer, ng/mL22,616.73 ± 23,765.736453.04 ± 1,887.611.00 (1 00-1.00) <b>&lt;.001</b> 1.00003 (1.0002-1.0004) <b>&lt;.001</b> Hospital length of stay, days1356 ± 14.798.84 ± 9.591.03 (1 02-1.05) <b>&lt;.001</b> NANA	History of hypertension							
No         31 (24.6)         702 (28.94)         NA         NA         NA         NA         NA           Negative D-dimer <sup>b</sup> Ves         0 (0)         357 (14.72)         0.02 (0.01-0.37) <sup>c</sup> <b>.008</b> 0 04 (0-0.29) <b>.001</b> No         126 (100)         2069 (85.28)         NA         NA         NA         NA           Maximum CRP, mg/L         202.2 ± 130.12         146.23 ± 111.81         1.00 (1 00-1.01) <b>.001</b> NA         NA           Maximum D-dimer, ng/ML         22,616.73 ± 0453.04 ± 0.01         1.00 (1 00-1.00) <b>.001</b> 1.00003 (1.00002-1.00004) <b>.000 .001</b> Hospital length of stay, days         13.56 ± 14.79         8.84 ± 9.59         1.03 (1 02-1.05) <b>.001</b> NA         NA	Yes	95 (75.4)	1724 (71.06)	1.25 (0.82-1.89)	.296	0.66 (0.39-1.14)	.131	
Negative D-dimer <sup>b</sup> O (0)         357 (14.72)         0.02 (0.01-0.37) <sup>c</sup> <b>.008</b> O 04 (0-0.29) <b>.001</b> No         126 (100)         2069 (85.28)         NA	No	31 (24.6)	702 (28.94)	NA	NA	NA	NA	
Yes         0 (0)         357 (14.72)         0.02 (0.01-0.37) <sup>c</sup> .008         0 04 (0-0.29)         <.001           No         126 (100)         2069 (85.28)         NA         NA         NA         NA           Maximum CRP, mg/L         202.2 ± 130.12         146.23 ± 111.81         1.00 (1 00-1.01)         <.001	Negative D-dimer <sup>b</sup>							
No         126 (100)         2069 (85.28)         NA         NA         NA         NA         NA           Maximum CRP, mg/L         202.2 ± 130.12         146.23 ± 111.81         1.00 (1 00-1.01)         <.001	Yes	O (O)	357 (14.72)	0.02 (0.01-0.37)	° .008	0 04 (0-0.29)	<.001	
Maximum CRP, mg/L         202.2 ± 130.12         146.23 ± 111.81         1.00 (1 00-1.01)         <.001         NA         NA           Maximum D-dimer, ng/mL         22,616.73 ± 23,765.73         6453.04 ± 1.00 (1 00-1.00)         .001         1.00003 (1.00002-1.00004) <.001	No	126 (100)	2069 (85.28)	NA	NA	NA	NA	
Maximum D-dimer, ng/mL         22,616.73 ± 23,765.73         6453.04 ± 1.00 (1 00-1.00)         <.001         1.00003 (1.00002-1.00004) <.001           Hospital length of stay, days         13.56 ± 14.79         8.84 ± 9.59         1.03 (1 02-1.05)         <.001	Maximum CRP, mg/L	202.2 ± 130.12	146.23 ± 111.81	1.00 (1 00-1.01)	<.001	NA	NA	
Hospital length of stay, days         13.56 ± 14.79         8.84 ± 9.59         1.03 (1 02-1.05)         <.001         NA         NA	Maximum D-dimer, ng/mL	22,616.73 ± 23,765.73	6453.04 ± 13,887.61	1.00 (1 00-1.00)	<.001	1.00003 (1.00002-1.000	04) <b>&lt;.001</b>	
	Hospital length of stay, days	13.56 ± 14.79	8.84 ± 9.59	1.03 (1 02-1.05)	<.001	NA	NA	

(Continued on next page)

#### Table. Continued.

	VTE development		Univar	riate analysis	Multivariate analysis		
Risk factor	Yes (n = 126)	No (n = 2426)	Crude OR (95% CI)	<i>P</i> value	aOR <sup>a</sup> (95% CI)	<i>P</i> value	
Median family income, \$	\$62,529.57± \$25,179.72	\$70,036.61± \$31,599.19	1.00 (1 00-1.00)	.009	0.99999 (0.99998-1.00000)	.07	
Foreign place of birth, %	11.87 ± 9.74	14.36 ± 10.79	0.98 (0.96-0.99)	.012	NA	NA	
Unemployment rate, %	9.79 ± 3.98	8.64 ± 4.16	1.07 (1.02-1.11)	.002	NA	NA	
Poverty rate for civilians aged >65 years. %	13.11 ± 7.81	11.22 ± 6.51	1.04 (1.01-1.06)	.002	NA	NA	

aOR, Adjusted odds ratio; CI, confidence interval; CLOT, coronavirus disease 2019 likelihood of thrombosis; CRP, C-reactive protein; ICU, intensive care unit; MOCHA, markers of coagulation and hemostatic activation; NA, not applicable; OR, odds ratio; VTE, venous thromboembolism. Boldface P values represent statistical significance.

<sup>a</sup>Firth's bias-reduced logistic regression.

<sup>b</sup>Defined as <574 ng/mL.

<sup>c</sup>Haldane-Anscombe correction.

**ROC Curve** 



Fig. Receiver operating characteristic (*ROC*) curve for the *CLOT* (coronavirus disease 2019 likelihood of thrombosis) prediction model.

Author Disclosures: O. Alabi: Nothing to disclose; M. Di: Nothing to disclose; M. Gaddh: Nothing to disclose; R. A. Meena: Nothing to disclose; F. B. Nahab: Nothing to disclose; R. E. Patzer: Nothing to disclose.

## **RS10**.

# Effect of Coronavirus Disease 2019–Related Delays of Scheduled Operations for Patients With Chronic Limb Threatening Ischemia

Jorge A. Miranda,<sup>1</sup> Max V. Wohlauer,<sup>2</sup> Jayer Chung,<sup>1</sup> Wissam Al-Jundi,<sup>3</sup> Riley Gillette,<sup>2</sup> Kathryn Colborn,<sup>2</sup> Robert Cuff,<sup>4</sup> Joseph L. Mills<sup>1</sup>. <sup>1</sup>Baylor College of Medicine, Houston, Tex: <sup>2</sup>University of Colorado Denver, Denver, Colo; <sup>3</sup>Norfolk and Norwich University Hospitals, Norfolk, United Kingdom; <sup>4</sup>Michigan State University, Grand Rapids, Mich

**Objective**: The goal of the VASCC (vascular surgery COVID-19 [coronavirus disease 2019] collaborative) study was to determine the influential characteristics of a population with severe peripheral artery disease (PAD) and/or chronic limb threatening ischemia (CLTI) during the COVID-19 pandemic for whom postponement of scheduled procedures could have affected the outcomes.

**Methods:** VASCC, founded in March 2020, is an international multicenter observational study of a subset of PAD/CLTI patients for whom planned interventions were postponed during the COVID-19 pandemic surge. The following interim data were collected for 165 patients in the United States: demographics, comorbidities, wound ischemia foot infection (Wifl) stage, indication and planned surgery, location of surgery, time delay, change in surgical plan, and adverse events. Descriptive statistics were used for the interim data.

Results: For the 165 index patients, the average length of delay to surgery was 59.3 ± 50.4 days (median, 47.0 days; range, 1-241). Of the 165 patients, 66 had a baseline WIfl grade and stage available. Wound grades of 1 and 3 were equally prevalent (n = 22; 33.3%), and an ischemia grade of 3 was most prevalent (n = 56; 84.8%). Foot infection grade 0 was the most prevalent (n = 53; 80.3%). WIfI clinical stage 3 (indicating a moderate risk of amputation) was the most prevalent. The frequency of the surgical indications (Table) was as follows: severe claudication, n = 36 (21.8%); minor tissue loss, n = 33 (20.0%); rest pain, n = 27 (16.4%); and major tissue loss, n = 26 (15.8%). Intervention for a threatened bypass was required for six patients (3.6%) and for critical in-stent stenosis in three (1.8%). In the severe claudication group, four patients (11.1%) developed rest pain and one (2.7%) experienced minor tissue loss during the delay for the planned intervention. In the minor tissue loss group, one patient (3.0%) had progressed to extensive tissue loss. From the interim cohort, eight delayed patients (4.8%) required conversion of planned, elective surgery to emergent surgery (Table). The indications for emergency surgery were progressive tissue loss for five (62.5%), critical in-stent restenosis for two (25%). and threatened bypass for one patient (12.5%). The primary major adverse event after emergency surgery was major limb amputation for four of the eight patients (50%). At the last follow-up, 10 of the 165 limbs (6.1%) have required a major limb amputation and 7 (4.2%) a minor amputation.

**Conclusions:** COVID-19–related delays in intervention for patients with severe PAD or CLTI led to a low observed, yet unpredictable, rate of decompensation. Nonetheless, for the patients who had required conversion of planned, elective surgery to an emergency operation, the outcomes were catastrophic, with a 50% risk of major amputation.

Variable	Patients	Worsening from original indication (N = 165)	Indication for emergency surgery (N = 8)
Indication for planned surgery $(N = 165)$	/		
Asymptomatic	6 (3.6)	O (O)	0 (0)
Claudication			
Mild	9 (5.5)	1 (11.1)	O (O)
Moderate	16 (9.7)	O (O)	0 (0)
Severe	36 (21.8)	5 (13.9)	0 (0)
Rest pain	27 (16.4)	O (O)	0 (0)
Tissue loss			
Minor	33 (16.4)	1 (3)	0 (0)
Extensive	26 (15.8)	O (O)	5 (62.5)
Threatened bypass	6 (3.6)	O (O)	1 (12.5)

Table. Indications for planned surgery and emergency adverse events

(Continued on next page)